Taiwan Liposome forms JV with Jixi in China

Taiwan Liposome Co. Ltd. (TPEx:4152) said it entered into a joint venture with Jixi Biotechnology to promote and market Taiwan Liposome's drugs more efficiently in China.

Jixi will invest $20 million to purchase a partial stake in TLC Biopharmaceuticals (H.K.) Ltd., a Hong Kong subsidiary of Taiwan Liposome, through which Taiwan Liposome's products will be commercialized in China. Jixi has the option to increase its stake for total payments of $50 million. Taiwan Liposome said it maintains a majority stake in its Hong Kong subsidiary...